4 Comments
Jun 17, 2020Liked by Zach Haigney

To clarify, MAPS is required to run 2 x 100-person phase 3 trials. Interim analysis confirmed they didn't need to enroll more than 100 people for that first trial (and due to COVID, FDA offered to end early with only 90 subjects). Another phase 3 trial (MAPP2) of 100 people is still needed, so unfortunately there are no savings on time or money.

Expand full comment

Is the pump&dump image for Champignon, nee Apotheosis? I also couldn't find the infor for Silo Wellness, but did see that this just happened https://www.globenewswire.com/news-release/2020/06/17/2049450/0/en/Yukoterre-Resources-Announces-Proposed-Reverse-Takeover-by-Psychdelics-Company-Silo-Wellness.html

Expand full comment